The stock of Catheter Precision Inc (VTAK) has gone up by 2.11% for the week, with a 28.71% rise in the past month and a -70.25% drop in the past quarter. The volatility ratio for the week is 14.42%, and the volatility levels for the past 30 days are 20.22% for VTAK. The simple moving average for the last 20 days is -19.30% for VTAK stock, with a simple moving average of -85.41% for the last 200 days.
Is It Worth Investing in Catheter Precision Inc (AMEX: VTAK) Right Now?
VTAK has 36-month beta value of -0.42. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VTAK is 2.50M, and currently, short sellers hold a 7.35% ratio of that float. The average trading volume of VTAK on November 14, 2024 was 3.50M shares.
VTAK) stock’s latest price update
Catheter Precision Inc (AMEX: VTAK)’s stock price has plunge by 10.47relation to previous closing price of 0.43. Nevertheless, the company has seen a 2.11% surge in its stock price over the last five trading sessions. accesswire.com reported 2024-11-13 that FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024. Highlights of the third quarter include: Commercial Endeavors Marie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.
Analysts’ Opinion of VTAK
Many brokerage firms have already submitted their reports for VTAK stocks, with Piper Jaffray repeating the rating for VTAK by listing it as a “Neutral.” The predicted price for VTAK in the upcoming period, according to Piper Jaffray is $1.50 based on the research report published on August 13, 2019 of the previous year 2019.
Maxim Group, on the other hand, stated in their research note that they expect to see VTAK reach a price target of $23. The rating they have provided for VTAK stocks is “Buy” according to the report published on November 02nd, 2018.
VTAK Trading at -0.41% from the 50-Day Moving Average
After a stumble in the market that brought VTAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.28% of loss for the given period.
Volatility was left at 20.22%, however, over the last 30 days, the volatility rate increased by 14.42%, as shares surge +11.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.17% lower at present.
During the last 5 trading sessions, VTAK rose by +2.11%, which changed the moving average for the period of 200-days by -91.66% in comparison to the 20-day moving average, which settled at $0.5949. In addition, Catheter Precision Inc saw -88.13% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VTAK starting from JENKINS DAVID A, who purchase 9,528 shares at the price of $0.60 back on Jan 23 ’24. After this action, JENKINS DAVID A now owns 329,856 shares of Catheter Precision Inc, valued at $5,694 using the latest closing price.
JENKINS DAVID A, the Executive Chairman and CEO of Catheter Precision Inc, purchase 9,528 shares at $0.43 during a trade that took place back on Jan 22 ’24, which means that JENKINS DAVID A is holding 320,328 shares at $4,092 based on the most recent closing price.
Stock Fundamentals for VTAK
Current profitability levels for the company are sitting at:
- -24.45 for the present operating margin
- 0.92 for the gross margin
The net margin for Catheter Precision Inc stands at -21.77. The total capital return value is set at -0.46. Equity return is now at value -49.81, with -30.71 for asset returns.
Based on Catheter Precision Inc (VTAK), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -0.83.
Currently, EBITDA for the company is -15.11 million with net debt to EBITDA at -0.09. When we switch over and look at the enterprise to sales, we see a ratio of 4.9. The receivables turnover for the company is 4.15for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.12.
Conclusion
To put it simply, Catheter Precision Inc (VTAK) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
